Benlysta May Reduce Need for Corticosteroids
Source: MedPage Today
In data from two large randomized controlled trials, belimumab was moderately associated with a higher probability of reducing the dose of corticosteroid and a greater average dose reduction over 52 weeks. Dose reduction occurred in 38.5% of belimumab users versus 30.9% of people receiving placebo while dose augmentation occurred in 18.4% versus 30.7% according to Ronald F. van Vollenhoven, MD, PhD, of the Academic Medical Center in Amsterdam, and colleagues of the Academic Medical Center in Amsterdam, and colleagues.
The study was funded by Human Genome Sciences and GlaxoSmithKline.